Breaking Finance News

Curis, Inc. (NASDAQ:CRIS) has been upgraded to Hold in a report by Zacks Investment Research today.

Just yesterday Curis, Inc. (NASDAQ:CRIS) traded 2.62% higher at $2.74. Curis, Inc.’s 50-day moving average is $2.02 and its 200-day moving average is $1.81. The last closing price is up 51.76% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 804,585 shares of CRIS traded hands, up from an average trading volume of 487,626

Zacks Investment Research has upgraded Curis, Inc. (NASDAQ:CRIS) to Hold in a report released on 10/04/2016.

Recent Performance Chart

Curis, Inc. (NASDAQ:CRIS)

Curis, Inc. has 52 week low of $1.25 and a 52 week high of $3.18 and has a market capitalization of $0.

In addition to Zacks Investment Research reporting its stock price target, a total of 5 brokers have issued a research note on the company. The average stock price target is $5.60 with 2 brokers rating the stock a strong buy, 4 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

Brief Synopsis On Curis, Inc. (NASDAQ:CRIS)

Curis, Inc. is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company's drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. Its product pipeline includes CA-170, which is an oral small molecule drug candidate; CA-4948, which is an oral small molecule drug candidate that is designed to inhibit the interleukin-1 receptor-associated kinase 4 (IRAK4) kinase; Erivedge, which is an orally bioavailable small molecule, and is designed to selectively inhibit the Hedgehog signaling pathway; CUDC-427, which is an oral, small molecule Smac mimetic that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins, and CUDC-305, which is an oral HSP90 inhibitor for the development in advanced lung cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *